REGENERON PHARMACEUTICALS, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
REGENERON PHARMACEUTICALS, INC. (REGN) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 0 shares for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-08.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2018-02-08
- REGENERON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2017-09-30 was 0.00 shares.
- REGENERON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2017-06-30 was 0.00 shares.
- REGENERON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2017-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2016-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2017 was 0.00 shares, a 100.00% decline from fiscal 2016.
- REGENERON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2016 was 61.00K shares.
- REGENERON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2015 was 0.00 shares.
- REGENERON PHARMACEUTICALS, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2014 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|
| 2017-12-31 | 0.00 shares 10-K · filed 2018-02-08 | |||
| 2017-09-30 | 0.00 shares 10-Q · filed 2017-11-08 | 0.00 shares 10-Q · filed 2017-11-08 | ||
| 2017-06-30 | 0.00 shares 10-Q · filed 2017-08-03 | 0.00 shares 10-Q · filed 2017-08-03 | ||
| 2017-03-31 | 0.00 shares 10-Q · filed 2017-05-04 | |||
| 2016-12-31 | 61.00K shares 10-K · filed 2018-02-08 | |||
| 2016-09-30 | 0.00 shares 10-Q · filed 2017-11-08 | 81.00K shares 10-Q · filed 2017-11-08 | ||
| 2016-06-30 | 0.00 shares 10-Q · filed 2017-08-03 | 121.00K shares 10-Q · filed 2017-08-03 | ||
| 2016-03-31 | 44.00K shares 10-Q · filed 2017-05-04 | |||
| 2015-12-31 | 0.00 shares 10-K · filed 2018-02-08 | |||
| 2015-09-30 | 308.00K shares 10-Q · filed 2016-11-04 | 0.00 shares 10-Q · filed 2016-11-04 | ||
| 2015-06-30 | 0.00 shares 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | 0.00 shares 10-Q · filed 2016-05-05 | |||
| 2014-12-31 | 0.00 shares 10-K · filed 2017-02-09 | |||
| 2014-09-30 | 4.03M shares 10-Q · filed 2015-11-04 | 0.00 shares 10-Q · filed 2014-11-04 | ||
| 2013-12-31 | 0.00 shares 10-K · filed 2015-02-12 | |||
| 2013-09-30 | 4.76M shares 10-Q · filed 2014-11-04 | 4.76M shares 10-Q · filed 2014-11-04 | ||
| 2012-12-31 | 4.76M shares 10-K · filed 2015-02-12 | |||
| 2012-09-30 | 4.76M shares 10-Q · filed 2013-11-05 | |||
| 2011-12-31 | 0.00 shares 10-K · filed 2014-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |